STAT | Reporting from the frontiers of health and medicine 中文 关注 STAT+：Pharmalittle：我们读到诺华和百时美施贵宝暂停细胞疗法试验、一款价值 48 万美元的抗癌药物等内容。 诺华和百时美施贵宝已暂停多项细胞疗法临床试验，而 48 万美元如今已成为癌症药物的常规价格。阅读今日最新的制药头条…… STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more statnews.com STAT | Reporting from the frontiers of health and medicine 中文 RSS thenote.app
